Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
1997 1
1999 1
2002 1
2004 1
2005 2
2006 5
2007 14
2008 7
2009 12
2010 8
2011 4
2012 14
2013 11
2014 9
2015 7
2016 7
2017 5
2018 5
2019 2
2020 3
2021 1
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

103 results
Results by year
Filters applied: . Clear all
Page 1
CLCN2-Related Leukoencephalopathy.
Min R, Depienne C, Sedel F, Abbink TEM, van der Knaap MS. Min R, et al. Among authors: sedel f. 2015 Nov 5 [updated 2021 May 20]. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Mirzaa GM, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2022. 2015 Nov 5 [updated 2021 May 20]. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Mirzaa GM, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2022. PMID: 26539602 Free Books & Documents. Review.
Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Cree BAC, Cutter G, Wolinsky JS, Freedman MS, Comi G, Giovannoni G, Hartung HP, Arnold D, Kuhle J, Block V, Munschauer FE, Sedel F, Lublin FD; SPI2 investigative teams. Cree BAC, et al. Among authors: sedel f. Lancet Neurol. 2020 Dec;19(12):988-997. doi: 10.1016/S1474-4422(20)30347-1. Epub 2020 Oct 23. Lancet Neurol. 2020. PMID: 33222767 Clinical Trial.
MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled study.
Tourbah A, Lebrun-Frenay C, Edan G, Clanet M, Papeix C, Vukusic S, De Sèze J, Debouverie M, Gout O, Clavelou P, Defer G, Laplaud DA, Moreau T, Labauge P, Brochet B, Sedel F, Pelletier J; MS-SPI study group. Tourbah A, et al. Among authors: sedel f. Mult Scler. 2016 Nov;22(13):1719-1731. doi: 10.1177/1352458516667568. Epub 2016 Sep 1. Mult Scler. 2016. PMID: 27589059 Free PMC article. Clinical Trial.
[Treatable hereditary neuro-metabolic diseases].
Sedel F, Lyon-Caen O, Saudubray JM. Sedel F, et al. Rev Neurol (Paris). 2007 Oct;163(10):884-96. doi: 10.1016/s0035-3787(07)92631-4. Rev Neurol (Paris). 2007. PMID: 18033024 Review. French.
Myoclonus and dystonia in cerebrotendinous xanthomatosis.
Lagarde J, Roze E, Apartis E, Pothalil D, Sedel F, Couvert P, Vidailhet M, Degos B. Lagarde J, et al. Among authors: sedel f. Mov Disord. 2012 Dec;27(14):1805-10. doi: 10.1002/mds.25206. Epub 2012 Oct 31. Mov Disord. 2012. PMID: 23115103 Review.
103 results